Bone and CVS health

BONE HEALTH

• Women should be given information and advice on how to optimise their bone health.
• HRT is the preferred choice of treatment for the prevention and management of osteoporosis in women with POI, and bisphosphonates should not be first line treatment in this age group.
• Bisphosphonates can remain incorporated in bone matrix for a long period of time, and there is limited evidence assessing the long-term reproductive implications associated with their use. Caution should therefore be taken with their use in women of the reproductive age group.
• For information on monitoring bone health in women with POI, see assessment section.

CARDIOVASCULAR HEALTH

• Women should be given information on how to optimise their cardiovascular (CVS) health.
• For information on monitoring CVS health see assessment section.